SMMT · Categories · Downgrades
SMMT - Analyst downgrades
Summit Therapeutics Inc. (SMMT) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for SMMT
- Summit Therapeutics downgraded by Bernstein with a new price targetBernstein downgraded Summit Therapeutics from Mkt Perform to Underperform and set a new price target of $8.30
- Summit Therapeutics downgraded by H.C. WainwrightH.C. Wainwright downgraded Summit Therapeutics from Buy to Neutral
- Summit Therapeutics downgraded by Jefferies with a new price targetJefferies downgraded Summit Therapeutics from Buy to Hold and set a new price target of $15.00
- Summit Therapeutics downgraded by Citigroup with a new price targetCitigroup downgraded Summit Therapeutics from Buy to Neutral and set a new price target of $23.00 from $19.00 previously
Other SMMT categories
Is something on this page wrong? Request a change